Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;63(7):729-736.
doi: 10.1111/myc.13092. Epub 2020 May 6.

Risk factors for mortality in patients with pulmonary mucormycosis

Hyo-Ju Son  1   2 , Joon Seon Song  3 , Sungim Choi  4 , Jiwon Jung  1 , Min Jae Kim  1 , Yong Pil Chong  1 , Sang-Oh Lee  1 , Sang-Ho Choi  1 , Yang Soo Kim  1 , Jun Hee Woo  1 , Sung-Han Kim  1
Affiliations

Risk factors for mortality in patients with pulmonary mucormycosis

Hyo-Ju Son et al. Mycoses. 2020 Jul.

Abstract

Background: Pulmonary mucormycosis (PM) represents a serious burden in terms of morbidity and mortality in immunocompromised patients. Studies of prognostic factors in patients with PM are limited and have involved small numbers of patients.

Methods: Adult patients diagnosed with proven and probable PM according to the modified definitions of the EORTC/MSG 2008 in a tertiary hospital in Seoul, South Korea, between 2008 and 2019 were retrospectively enrolled.

Results: A total of 49 patients including 31 (63%) with proven PM and 18 (37%) with probable PM were enrolled. The 90-day mortality rate was 49% (24/49). Neutropenia, thrombocytopenia, use of voriconazole at clinical suspicion, positivity of non-sterile culture, use of steroid and treatment without surgery were more common in fatal cases than non-fatal cases. Voriconazole use at clinical suspicion for invasive mould pneumonia (OR 6.91, P = .01) and prolonged neutropenia (OR 4.86, P = .03) were independent risk factors for mortality. Voriconazole use at clinical suspicion was associated with positive galactomannan (GM) assay (OR 5.93, P = .02) and history of invasive pulmonary aspergillosis (OR, 6.88, P = .05).

Conclusion: About half of the patients with PM died within 90 days of diagnosis, and fatal outcomes were common in patients with prolonged neutropenia and empirical voriconazole use. Caution is needed in using voriconazole even in patients with positive GM results and prior histories of invasive pulmonary aspergillosis in whom PM cannot be ruled out by differential diagnosis.

Keywords: galactomannan; invasive pulmonary aspergillosis; mortality; mucormycosis; neutropenia; polyenes; pulmonary mucormycosis; voriconazole.

PubMed Disclaimer

References

REFERENCES

    1. Dimitrios P, Kontoyiannis REL. Agents of Mucormycosis and Entomophthoramycosis. In: Bennett JE, Dolin R, Blaser MJ ed. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th edn. Philadelphia, PA: Elsevier; 2020:3117-3130.
    1. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Inf Dis. 2005;41:60-66.
    1. Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am. 2016;30:143-163.
    1. Choi S, Song JS, Kim JY, et al. Diagnostic performance of immunohistochemistry for the aspergillosis and mucormycosis. Mycoses. 2019;62:1006-1014.
    1. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 1990s;30:851-856.

MeSH terms

LinkOut - more resources